Roche bets again on Io­n­is in Hunt­ing­ton’s, Alzheimer's

Roche is again pair­ing up with its decade­long part­ner Io­n­is Phar­ma­ceu­ti­cals, pay­ing $60 mil­lion up­front for the ex­clu­sive rights to two RNA as­sets, the com­pa­nies …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER